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Abstract
Objective: Melancholic depression is a lifetime diagnosis, typically with 
recurrent episodes. Melancholia, a syndrome with a long history and distinctive 
psychopathological features, is differentiated from major depression by the 
DSM-IV specifiers and partly described in the International Classification 
of Diseases – 10th edition. Within the present classification, it is frequently 
seen in severely ill patients with major depression and bipolar disorder. 
Nevertheless, it has a distinctive psychopathology and biological homogeneity 
in clinical experience and laboratory test markers, and it is differentially 
responsive to specific treatment interventions according to international 
studies. The objective of this study is to review the literature published by 
Latin American authors about Melancholia. Method: We conducted a 
systematic search to identify scientific literature published by Latin American 
authors gathering information relevant to the revision of the classification 
of mental and behavioral disorders in patients with melancholic depression 
of the International Classification of Diseases – 10th edition. The review 
was specifically focused on literature from Brazil and Latin America in 
order to examine the specific Latin American contribution for the study of 
melancholia as a distinct entity. Results and Conclusion: Melancholia can 
be identified as a separate mood disorder with unique psychopathology and 
psychoneuroendocrinology, worthy of separate attention in the classification 
systems. We therefore suggest that melancholia be positioned as a distinct, 
identifiable mood disorder that requires specific treatment. 
Descriptors: Latin America; Depressive disorder; Diagnosis; International 
Classification of Diseases; Evaluation studies    
Resumo
Objetivo: A depressão melancólica é um diagnóstico psiquiátrico de 
história de vida, geralmente com episódios recorrentes. Melancolia é uma 
síndrome com longa duração e características específicas de psicopatologia, 
insuficientemente diferenciada de depressão maior por um especificador no 
DSM-IV e parcialmente descrito nos critérios da Classificação Internacional 
de Doenças-10ª Edição. Dentro da classificação atual, é frequentemente 
vista em pacientes gravemente doentes com depressão e transtorno bipolar. 
No entanto, a melancolia possui uma homogeneidade psicopatológica 
e biológica distinta na experiência clínica e nos marcadores de testes 
laboratoriais, e é diferencialmente sensível às intervenções terapêuticas 
específicas. O objetivo deste estudo é revisar a literatura de artigos publicados 
por autores latino-americanos sobre a melancolia. Método: Realizou-se 
busca de artigos latino-americanos de informações relevantes para a revisão 
da Classificação Internacional de Doenças-10ª Edição de transtornos mentais 
e comportamentais em pacientes com depressão melancólica. Foi avaliada a 
qualidade do design de todos os estudos e realizada uma revisão abrangente 
sobre o assunto, com o objetivo de considerar a contribuição latino-americana 
para inclusão da melancolia como uma entidade distinta na futura Classificação 
Internacional de Doenças-11ª Edição. Resultados e Conclusão: Os estudos 
latino-americanos fundamentam o diagnóstico da melancolia com uma 
psicopatologia e psiconeuroendocrinologia própria que fundamentam ser 
reconhecida como um transtorno de humor identificável e merecedor de 
uma atenção específica nos sistemas de classificação, como um transtorno de 
humor distinto, identificável  e especificamente tratável.
 
Descritores: América Latina; Transtorno depressivo; Diagnóstico; 
Classificação Internacional de Doenças; Estudos de avaliação 
Introduction
Melancholia is the only condition whose original name survived 
from the Hippocratic classification of diseases based on the four 
humors. The humoral theory viewed illnesses as disturbances in the 
equilibrium of the humors. Hippocrates thought that melancholia 
was caused by a humor called ”black bile” and that treatment should 
consist of bloodletting.1,2 From a historical perspective, there have been 
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great changes in diagnostic classification systems, from descriptive-
phenomenological approaches like that of Kraepelin, to interpretative-
based approaches, such as Freud’s.3 Afterwards, new classifications 
were proposed, endogenous depressions were included among mood 
disorders, and the depressive syndrome was divided into endogenous 
or reactive and cyclothymic disorders.1 Recently, major depression is 
sub-divided into multiple sub-groups – some categorical (e.g. psychotic, 
melancholic, catatonic), some etiological (e.g. postpartum, seasonal), 
and some dimensional or weighted (involving severity, chronicity, 
and persistence).2,4-6
The results of classification efforts in the 1980s and early 1990s 
supported the distinction between unipolar (depression) and bipolar 
(manic–depressive) disorders, which is reflected in recent editions of 
the Diagnostic and Statistical Manual of Mental Disorders (DSM)4 
and the International Classification of Diseases (ICD-10).5 Although 
the concept of melancholia — a biologically-based, severe depressive 
syndrome, can be traced back to antiquity, the diagnostic validity of 
this construct remains uncertain. In particular, there has been extensive 
discussion on whether non-melancholic and melancholic depression are 
two separate conditions or reflect differences in the severity of a single 
syndrome.6,7 In the section concerning mood and affective disorders 
of the ICD-10 (F30-39), the authors state that the “relationship 
between etiology, symptoms, underlying biochemical processes, 
response to treatment, and outcome of mood [affective] disorders is 
not yet sufficiently well understood to allow their classification in a 
way that is likely to meet with universal approval”,5 and continue 
explaining that the “main criteria by which the affective disorders 
have been classified have been chosen for practical reasons, in that 
they allow common clinical disorders to be easily identified. Single 
episodes have been distinguished from bipolar and other multiple 
episode disorders because substantial proportions of patients have 
only one episode of illness, and severity is given prominence because 
of implications for treatment and for provision of different levels of 
health services. It is acknowledged that the symptoms referred to here as 
‘somatic’ could also have been called ‘melancholic’, ’vital’, ‘biological’, 
or ‘endogenomorphic’, and that the scientific status of this syndrome 
is in any case somewhat questionable. It is hoped that the result of its 
inclusion will lead to widespread critical appraisal of the usefulness 
of its separate identification. The classification is arranged so that this 
somatic syndrome could be recorded by those who so wish, but can also 
be ignored without loss of any other information”.5 
The DSM-III and ICD-10 were expected to bring about advance 
to nosology, as they consisted of procedures and defined systems based on 
manifest behaviors. Since then, the core entity of mood disorders became 
a uniform major depressive disorder with modifiers for differences in 
subtypes (e.g., psychotic or atypical), and for circumstances presumed to 
have clinical significance (e.g., seasonal or postpartum depression).7,8 The 
early description of major depressive disorder in the DSM-III (preserved in 
the DSM-IV and DSM-IV-TR) clearly defined the melancholic features 
of depression; although the DSM-IV criteria for melancholia challenges 
the recognition of a detailed subcategory of severe patients described by a 
specific symptom outline, not triggered by stress, approachable by biological 
treatment, and related to a greater incidence of organic dysfunctions (for 
instance, non-suppression in the dexamethasone suppression test and shorter 
rapid eye movement sleep latency).9,10 In the DSM, some of the specifiers 
would appear categorical (as melancholia, for example), but this is less 
obvious when decision charts are reviewed. For instance, a depressive 
patient with anhedonia, early insomnia, psychomotor dysfunction and 
weight change would meet criteria for both major depression and the 
melancholic subtype. This is irrational if the “specifier” is intended to 
describe a subtype of depression.
In order to specify melancholic depression, the DSM-IV criteria 
are more similar to the DSM-III than to the DSM-III-R criteria. 
Lafer et al. have argued that the DSM-IV criteria for melancholia 
represent a return to the older, perhaps stricter, DSM-III definition.11 
The key symptoms for a diagnosis of major depression in the DSM-IV 
are the same, except that the newer version comprises also persistent 
anhedonia or unreactive mood, while the DSM-III requires both. The 
DSM-IV criteria for melancholia differ from DSM-III-R criteria in 
respect to the absence of the item “no significant premorbid personality 
disturbance, previous response to treatment and prior episode followed 
by complete recovery,” and to the inclusion of “excessive guilt” and 
“distinct quality of mood” (Table 1).
Many authors also suggest that the concept of melancholy should 
be recovered. Ruiz-Doblado, in an interesting non-systematic review 
named Sacrificing validity for feasibility in psychopathology: Seeing 
through a dark glass, argued that melancholy is one of the few diseases 
that remained valid over more than two millennia in the psychiatric 
vocabulary.12 Since Hippocrates, the term includes melancholic 
mood disturbances of particular intensity, delusional symptoms and 
vegetative symptoms (loss of appetite, weight, libido, altered circadian 
rhythms).12
Rush and Weissenburger proposed that “melancholic depression is a 
type of depression that has not been precipitated by stress; has a biological 
etiology; goes with unresponsiveness to environmental events; responds 
to somatic therapies but not psychotherapy; is seen in patients without 
personality pathology; is characterized by a special symptom pattern”.9 
The symptoms of psychomotor retardation, late insomnia, early morning 
worsening, weight loss, psychomotor agitation, and guilt are included in 
most of the diagnostic systems.9  
The Australian group of Parker et al. has increased the validity 
of the diagnosis of major depression through various studies over 
the last two decades.13 The essential characteristics of melancholy 
according to these authors include psychomotor retardation and 
different quality of affect. The group advocates for the recovery of 
the old concept of melancholy in future classifications and regrets 
the delay in doing it.14
Parker and Brotchie,15 in a special article for a supplement of 
the Revista Brasileira de Psiquiatria, stated that the features most 
commonly found were severity, psychomotor retardation, lack of a 
precipitant, unreactive mood, older age, not immature or hysterical, 
adequate personality, not hypochondriacal, distinct quality of mood, 
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reinstitution of the definition of melancholia, the establishment 
of a duration criterion, and the inclusion of a secondary criterion 
associating laboratory findings of non-suppression of cortisol, 
high nighttime cortisol levels, or decreased REM latency or other 
characteristic sleep abnormalities6-11,13-15,18 (see Table 2).
Our aim is to review Brazilian and Latin American evidence 
relevant to the revision of the classification of mental and behavioral 
disorders in patients with melancholic depression in the ICD-10. The 
purpose of the review is to focus specifically on literature from Latin 
America and to consider the particular contribution of this region 
for the inclusion of melancholia as a distinct entity in the ICD- 11.
Method
Two literature searches were conducted. In the first, the search 
expression ‘‘Melancholy” OR ‘‘Melancholia“ was entered into the 
search fields of the following electronic databases: Ovid Medline(R) 
In-Process & Other Non-Indexed Citations and Ovid MEDLINE; 
Journals@Ovid Full Text; Books@Ovid; BIOS Previews; ISI Web of 
Knowledge; ISI Proceedings; EMBASE Classic+EMBASE; Medline; 
PsycINFO; SCOPUS; SciELO; Psych Articles; IBECS; LILACS; 
BIREME; and the Brazilian Psychiatric Index.
In the second search, the expression ‘‘Melancholy” OR ‘‘Melancholia” 
was entered into each of the databases in combination with the names 
of 12 countries and with “Latin America” (“Argentina OR Bolivia 
OR Brazil OR Chile OR Colombia OR Costa Rica OR Cuba OR 
diurnal mood variability, delusions/paranoid features, and guilt. 
Features less consistently related to the endogenous factor across studies 
were late insomnia, psychomotor agitation, diurnal mood variation, 
weight loss, and obsessional symptoms or personality. 
The DSM-IV structure is mainly dimensional, major depression 
is mostly differentiated from depressive disorders by severity (for 
instance, length and number of symptoms differentiate major 
depression disorder and dysthymia), chronicity, and relapse. Every 
attempt to describe melancholia as a different entity is likely to fail 
if DSM-IV diagnostic criteria are used, and thus the validation of 
melancholia as a significant depressive subtype is discouraged.13-15
There is increasing data supporting that depressive disorders 
include a group of conditions which may be different in regard to 
the activity of the hypothalamus–pituitary–adrenal (HPA) axis, 
immune functions, and treatment response. Besides melancholia, 
a range of disorders may be related to increased activation of the 
hypothalamic-pituitary-adrenal (HPA) axis.16 Juruena et al. suggested 
the hypothesis that “continuous stress system dysfunction, characterized 
by either hyper- or hypoactivity of the HPA axis, play a role in various 
pathophysiological conditions”, including melancholic depression and 
treatment-resistant depression.10,16 Clinical and biochemical features 
of depression, especially of the melancholic subtype, closely resemble 
those that occur during acute stress, which is accompanied by the 
activation of the sympathetic nervous system and the HPA axis.2,16,17 
In recent years, an important movement has proposed the 
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Mexico OR Paraguay OR Peru OR Uruguay OR Venezuela OR 
Latin America”). See Figure 1 for details on the search procedures.
Results
The searches using the expression ‘‘Melancholy” OR ‘‘Melancholia” 
in combination with the names of 12 countries and Latin America 
yielded a total of 177 articles. Search results were refined by analysis of 
the abstracts of retrieved articles. Repeated references, duplicated data, 
and articles using a psychoanalytic approach were excluded, together 
with articles written in languages other than English, Portuguese, 
and Spanish. Data were systematically extracted from 127 articles 
entered in a review table. Forty-five articles were selected after filtering 
with the exclusion criteria (detailed in Figure 1), 12 of which were 
excluded due to repetition across databases, and a total of 33 articles 
were included in this review. Selected articles were then assigned to 
different categories for analysis: History, Classification and Diagnosis, 
Neurobiology, and Comorbidity.
1. History
Vidal described the first case of melancholia in the River Plate.19 
Cabrera’s was the first case of melancholia reported in the history of 
Latin America. The author argued that melancholia could not have 
appeared prior to the Renaissance age: it was necessary that Europeans 
were in a situation to achieve an ample point of individual distinction 
so that they could feel in charge for their actions by guilt deteriorating 
into melancholia.19 
Elferink, in a non-systematic review, studied the occurrence of 
mental disorders among the Incas in ancient Peru.20 The absence of 
written documents of pre-Columbian contacts and the chroniclers’ 
relative lack of medical knowledge create difficulties in precisely 
identifying the types of mental disorders that existed among the Incas. 
Melancholia affected not only the common people, but the family of 
the Inca emperor as well. The Incas considered all diseases to be the 
result of a disturbed relation with supernatural forces, and treated 
mental diseases with a mixture of religious/magic acts and medicinal 
plants. The dominance of melancholia among the Incas sets them 
apart from the Spanish and Aztec cultures, where no specific mental 
disorder preponderated.20 Silva reviewed the term melancholia and 
analyzed the difficulties in defining this condition at the beginning of 
the Modern Age. The author studied the relationship of melancholia 
with sadness and, mainly, with the production of delirium and 
fantasies according to the language of the medicine of the soul of the 
16th and 17th centuries.21,22
Spanemberg and Juruena, in a non-systematic review concerning 
historical and nosological aspects, described that in “the Greek 
Hippocratic School, dysthymia was considered as part of the concept 
of melancholia”.23 Thus, lethargic, anxious, and insecure individuals 
were predisposed to melancholic temperament. The review mentioned 
that Galen of Pergamum (128-201 AD) described melancholy as a 
chronic and recurrent condition, which could be a primary disease of 
the brain or secondary to other diseases. Sorano of Ephesus described 
melancholic patients with symptoms of injury and as being paranoid 
and depressed. During the Renaissance, Robert Burton published the 
classic The Anatomy of Melancholy (1621). In this work, Burton 
listed old age, temperament, and genetic inheritance among the causes 
of melancholy, and also established it as a secondary cause of diseases 
of the body. In the 18th century, William Cullen (1710-1790), under 
the influence of the Enlightenment, associated melancholy with a 
primary instability of the brain and suggested “constraints” as the 
best remedy to lessen excitement. The term “depression” appeared in 
medical dictionaries in 1860 and was widely accepted and increasingly 
restricted the term “melancholy”. Esquirol (1772-1840) suggested 
that the word “melancholy” should be left to the use of poets, and 
Berrius stated that the term “depression” had supplanted the ancient 
“melancholy” due to the apparent impression of physiological and 
metaphorical fall of the functions implied.23
2.  Classification and diagnosis
Del Porto, in a non-systematic review, investigated melancholic 
features.24 The term “melancholy” has been employed in current 
classifications, such as the DSM-IV, to designate a subtype previously 
called “endogenous”, “vital”, “organic”, “somatic” or “endogenomorphic” 
depression. Considered by many as the prototype or nuclear syndrome 
of depression, melancholy - unlike other forms of depression – seems 
to be part of a more homogeneous group of conditions that respond 
better to biological treatments and in which genetic factors would be 
the main determinants. The review emphasized studies by Parker et 
al., which draw attention to the importance of psychomotor changes 
in melancholy, the main feature of this nosological category according 
to those authors. The concept of melancholia in the DSM-IV was 
revised in relation to the DSM-III-R, becoming more accurate and 
defining the subgroup studied more precisely.24 In normal mourning, 
individuals usually retain certain interests and respond positively to 
the environment when properly stimulated. Psychomotor inhibition 
characteristic of melancholic states are not observed in mourning. In 
a literature review concerning depressive states, the item “psychomotor 
retardation” was the common denominator in nine classification 
systems as a defining feature of melancholia.24 The most severe forms 
of psychotic depression were described by Kraepelin and named 
“fantastic melancholy”. This condition involved intense delusions and 
hallucinations, alternating states of arousal with violent stuporous 
states, along with slight clouding of consciousness. Motor immobility 
may present as stupor (called “melancholy stupor”) or as catalepsy 
(waxy flexibility). It should be noted that true melancholic stupor is 
very seldom observed nowadays.24 
In a non-systematic review with the title Sacrificing validity for 
feasibility in psychopathology: Seeing through a dark glass12 Ruiz-
Doblado debated the issue of nosological validity as an example of loss 
of diagnostic accuracy between melancholy and major depression.12
Pinzon Sanchez, in a large epidemiologic study conducted in the 
1970s in Colombia, reported a high incidence of depressive states in 
a Colombian psychiatric clinic.25 The total number of patients was 
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48,101, followed over a 2.5-year period, and data were presented 
in relation to sex, age, marital status, frequency of consultation, and 
services rendered. Depressive disorders accounted for 75.3% of all cases, 
and the following problems were found: depressive neurosis (43.2%); 
involuntary melancholy (13.8%); hypochondriac neurosis (11.9%); 
and cerebral dysthymia (6.4%). No reasons could be determined for 
the high incidence of depressive disorders in this geographical area. 25
Dratcu et al., in a case control study,26 emphasized the importance 
of cross-cultural investigations in psychiatry and revealed the need 
for standardized instruments to diagnose and assess depression. The 
authors described  the first application of the Montgomery-Asberg 
Depression Rating Scale (MADRS) in Brazilian patients, comparing 
the results with those obtained with the Hamilton Depression Rating 
Scale, the Visual Analogue Mood Scale (a self-rating scale), and the 
global clinical assessment of independent Brazilian psychiatrists. 
There were correlations between the MADRS and the three other 
assessment instruments, indicating that it is a useful and operational 
instrument to evaluate depressed patients. Moreover, all the patients, 
except one, met the Research Diagnostic Criteria (RDC) criteria for 
the endogenous subtype of major depressive disorder. In fact, a careful 
analysis and the practical application of these diagnostic criteria led 
to the observation of an overlap for the diagnosis of major depressive 
disorder and its endogenous subtype. In this study, published in the 
British Journal of Psychiatry in 1987,26 the authors state that the 
RDC and the DSM-III criteria are still a matter of discussion and 
controversy, and should not be used as a gold standard for diagnosis. 
The authors suggested that it is feasible that clinical psychiatrists have 
emphasized the endogenous features in diagnosing depression, as they 
are closer to the classical description of melancholia.26 
Calil, in a non-systematic review, examined the Latin American concept 
of depression and presented a Brazilian proposal.27 She argued that the 
diagnoses of depression have substantially increased over the last decades, 
thus compromising their validity. Actually, although depressed mood is 
considered the hallmark of depression, this disorder also involves cognitive, 
behavioral, and somatic changes. A conceptual model of depression, 
based on a bidimensional approach to its diagnosis, has been proposed 
by Sonenreich et al.28 According to this model, depression refers to the 
slowness of psychomotor functions (movements, thought, speech, perception) 
and narrowing of the inner field of experience. Biological, vital slowness 
(“lentification”) is experienced as “heaviness”, and thus reflects normal or 
pathological states. The inner field of experience means the global psychic 
activity or the synthesis of information processing provided by the body, 
the environment, and the meanings attributed to their relationships. 
This model conceives affection as a quality of experiences and not as 
a psychological function, and allows several research approaches. The 
relationship between the dimensions of the inner field of experience and 
the speed/velocity of psychomotor functions yields into separating depression, 
anxiety (a typical affection for some investigators), and mania. Some studies 
have attempted to validate this conceptual model.27,28
Banzato, in a non-systematic review, investigated classification 
issues in psychiatry: the move towards the ICD-11 and DSM-V.29 The 
analysis of taxometric studies favored the option for categorical models 
to explain some disorders (like melancholia and eating disorders) and 
for dimensional models to others (like depression, generalized anxiety, 
and posttraumatic stress disorder), supporting therefore a pluralistic 
view of psychiatric classifications. Besides, as a taxon does not require 
a biological cause, the author recommends treating the categorical 
versus dimensional issue and the problem of causation separately.29
Lafer et al., using a case control design, studied 176 consecutive 
outpatients with unipolar depression, of which 40 (22.7%) fulfilled 
the DSM-III-R diagnostic criteria and 29 (16.5%) met DSM-
IV criteria for melancholia specifier.11 Patients with DSM-IV 
melancholia had greater mean scores in dimensions of clinical severity 
as paralleled with those who met the DSM-III-R diagnosis. The data 
suggested that the diagnostic criteria for melancholia recommended in 
the DSM-IV are more limiting and define a more severely depressed 
population than criteria in the DSM-III-R.
Gentil et al., in a case control study, compared the efficacy and 
tolerability of antidepressants in outpatients with major depression 
with and without melancholia.30 This was an eight-week, multicenter, 
randomized, double-blind, parallel group comparison. Outpatients 
with DSM-IV major depression, a minimum score of 20 in the 21-
item Hamilton Depression Rating Scale (HAM-D), and depressive 
symptoms for at least one month were enrolled. The primary 
efficacy variables were the final on-therapy scores on the HAM-D, 
Montgomery–Asberg Depression Rating Scale (MADRS), and Clinical 
Global Impression severity scales. One hundred and 16 patients were 
randomized, and 115 were evaluated. Additional analyses were 
performed for sub-groups of patients as follows: with or without long 
duration of current episode (defined as greater or equal to the median: 
20 weeks); with or without long duration of depressive illness from 
the first episode, as determined with the SADS-L (greater or equal to 
the median: 7 years); and with or without melancholia (according 
to DSM-IV criteria). The pre-treatment scores in the total HAM-D, 
MADRS, CGI-severity of illness, and SCL-90 were significantly 
greater in the sub-group with melancholia (p < 0.05).30
The Brazilian Medical Association, in a systematic review, proposed 
guidelines for the treatment of depression, describing prevalence 
rates, demographics, disability, diagnoses and sub-diagnoses, efficacy 
of pharmacological and psychotherapeutic treatment, and costs and 
side-effects of different classes of drugs available in Brazil.31,32 
In a cross-cultural approach, Fleck et al. applied the Hamilton 
Rating Scale for Depression to 130 depressed inpatients in France 
and Brazil.33 Items were factorized, with three factors obtained in 
France and four in Brazil. The first factor included the core symptoms 
of depression (melancholic features) in both samples. Qualitative 
and quantitative differences between the Brazilian and French 
samples appeared in relation to the anxiety factor. Insomnia items 
appeared as another factor for both groups. Principal component 
analysis for depressive inpatients in these two countries showed a 
similar structure. The differences observed concerned the way in 
which anxiety items were distributed.33 
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Caldieraro, in a Master’s dissertation, compared the prevalence of 
psychotic symptoms in non-melancholic and melancholic depression 
in one hundred eighty-one patients with unipolar major depressive 
disorder.34 Melancholia diagnoses were made using both the DSM-IV-
TR criteria and the sign-based (CORE) rating system of psychomotor 
disturbance. Melancholic patients differed from non-melancholic ones 
in respect to symptom severity, suicidal ideation, axis I comorbidities, 
personality styles, and parental care measures. The results indicated 
a much higher percentage of patients with a melancholia diagnosis 
than did the CORE measure. The prevalence of psychosis was 
significantly higher in melancholic patients. But there was a gradient 
in the intensity of depressive symptoms among non-melancholic and 
melancholic patients, not influenced by psychotic status.34
Busnello et al., in a cross-sectional study, evaluated the Version for 
Primary Care (ICD-10 PC), prepared by the Division of Mental 
Health of the World Health Organization (WHO).35 Community 
general practitioners (CGP) were trained in this version and followed 
a field trial designed by the WHO. The data about the reliability of 
mental diagnosis attributed by nine pairs of CGP to 460 patients 
in their first appointments with Cohen’s Kappa for mental disorder 
diagnoses was 0.79 (CI 95%: 0.69–0.88), but the indices for 
depression (F31) and mixed anxiety and depression (F 41.2) were 
lower: 0.66 (CI-95%: 0.57-0.75) and 0.42 (CI-95%: 0.38-0.56).35
3. Neurobiology
In the pioneering study A Dualistic Approach to Some 
Biochemical Problems in Endogenous Depressions, Bueno 
and Himwich described vital depression as a syndrome including 
melancholia, lack of interest, retardation, decreased vitality, and 
suicidal ideas among delusional ideas of guilt and hopelessness that 
could be the result of disturbances in the indole metabolites which 
are increased in inhibited depressions and decreased in the agitated 
type.1 Such a dualistic approach may provide an explanation for the 
conflicting data on monoamine metabolism in endogenous depressions 
found both in the laboratory and in the clinical field. The clinical 
actions of the different types of therapy employed in the management 
of endogenous depressions, such as MAO inhibitors, iminodihenzyl 
derivatives, and electroconvulsive therapy may also find an explanation 
in this dualistic conception.1 
Early studies from the 1980s proposed the use of the dexamethasone 
suppression test (DST) as an auxiliary tool to diagnose the melancholic 
subtype of depression and pointed to the high specificity of the DST 
in melancholia.10,36 In the 1990s, however, several studies found that 
the sensitivity of the DST for the diagnosis of the melancholic subtype 
of major depression as defined by the DSM-III was low (35-45%), 
although its specificity was high (70-89%).10,16 
In a prospective study, Dratcu and Calil applied the DST to 40 
depressed patients, 40 healthy volunteers, and 40 patients with other 
psychiatric disorders, and used three different depression rating scales 
(MADRS, HAM-D, and the Visual Analogue Mood Scale).37 The 
authors showed differences between suppressing and non-suppressing 
patients concerning severity and treatment response and concluded 
that HPA axis variations appear to be state-dependent, inclined to 
improve upon remission of the depressive syndrome.37 
Juruena et al. described decreased HPA negative feedback leading 
to high concentrations of cortisol, as observed in melancholia.38 
Consistent with the presence of glucocorticoid receptor (GR) resistance 
in major depression, the authors described that, despite having higher 
plasma cortisol concentrations compared to controls, melancholic 
depressed patients exhibited no increase in plasma sialyltransferase 
levels. Sialyltransferases are a family of enzymes that participate in 
the oligosaccharide chain metabolism and are known to be stimulated 
by glucocorticoids via GR.16,39
Mello et al., in a non-systematic review, reported that depression 
(melancholia) is linked to hypercortisolemia in many patients, but 
that not all patients present this HPA axis dysfunction.40 Moreover, the 
authors concluded that the “dexamethasone suppression test is not the 
most accurate test to measure the hypothalamic-pituitary-adrenal axis 
function, and its use in the first published studies probably jeopardized 
the results”.40 Juruena et al. argued that “hypercortisolemia frequently 
occurs in patients with severe depression, melancholic, either psychotic 
or nonpsychotic type; it is linked to the presence of a polymorphism 
in the promoter of the serotonin transporter gene, with a history of 
childhood abuse or neglect, or other significant stressful experiences 
like the loss of a parent during childhood and temperament leading 
to alterations in the response to stress”.41 The authors concluded that 
“alterations of the hypothalamic-pituitary-adrenal axis depend on 
factors like severity and type of depression, genotype, history of exposure 
to stress, temperament, and probably resilience”. All these factors 
together result in an endophenotype thought to be prone to depression.41
In a case control study, Contreras et al. assessed 40 inpatients (19 psychotic 
and 21 nonpsychotic) with major depressive episode with melancholia 
according to DSM III-R criteria.42 The DST, thyroid stimulating 
hormone response to thyroid releasing hormone (TSH-TRF), and growth 
hormone response to growth hormone releasing factor (GH-GRF) tests 
were performed for all 40 inpatients. The data concerning instabilities of 
the HPA axis demonstrated around 80% of alterations in the 40 patients 
with melancholia, and that these alterations may be related to the presence 
of psychotic symptoms. Around 20% of the entire sample (15.8% with 
psychotic depression and 23.9% with non-psychotic depression) had no 
disturbances in hormonal axes. In the sample with melancholic patients, 
80% had disturbances in at least one hormonal axis, 40% in two axes, 
and 5% in all the three axes.42
Juruena and Cleare, in a non-systematic review of the literature 
subsequent to the publication of the DSM-IV and ICD-10, concluded 
that evidence “largely supports the validity of depression with atypical 
features, as distinct from melancholia and depression with neither 
atypical nor melancholic features”.43 The authors argued that “those 
with melancholic depression tend to feel worse in the morning, 
whereas those with atypical depression feel worse in the evening. 
While the debate concerning the best clinical criteria for atypical 
depression continues, the existing data propose that the neuroendocrine 
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pathophysiology is different and even opposite to that observed in 
patients with melancholic depression”43 (see details in Table 3). It 
is known that HPA axis overdrive and hypernoradrenergic function 
are related to melancholic depression, with elevated plasma cortisol 
levels and evidence for a strong corticotropin releasing factor (CRF) 
drive.44 In addition to HPA axis activity, different alterations of the 
serotonergic system may also play a significant function in melancholia. 
The authors argued that “the melancholic subtype with noradrenergic 
and HPA axis overdrive seems to be associated with reduced 5-HT1A 
autoreceptor function and, therefore, enhanced serotonergic activation 
of the HPA axis, as well as an acute phase immune reaction. The latter 
contributes to HPA axis stimulation and reduces negative feedback 
inhibition by corticosteroid receptors. The resulting hypercortisolemia 
can further impair 5-HT1A receptor functions, leading to a vicious 
circle, which may not be effectively resolved by most of the selective 
serotonin reuptake inhibitors (SSRI)”.40,43 It has been suggested that, 
while typical major depression (melancholic) can be characterized 
by an excessive activation of the physiological stress systems, the locus 
coeruleus noradrenergic system, and the hypothalamic-pituitary-
adrenal axis, opposite changes are present in atypical depression.43 
This almost complete opposite neuroendocrine disorder, with reduced 
HPA activity and CRF secretion, mediated by an increased negative 
feedback by cortisol and hyponoradrenergic function, was first 
described more than 15 years ago in atypical depression, and several 
studies have since substantiated the evidence for HPA hypofunction 
in this subgroup of depressed patients. While those with melancholic 
depression fail to suppress cortisol release after dexamethasone, those 
with atypical depression have an increased suppression of cortisol.43
4. Comorbidity
Soares et al., in a systematic review, addressed the historical evolution 
of the concept of melancholy in relation to the climacteric phase, with 
its diagnostic inaccuracies, heterogeneity, clinical psychopathology, 
and repercussions on the proposed therapeutics.44 In that review, the 
authors discussed the etiology and correlations with clinical disorders 
in peri-menopausal periods and models for a better understanding 
of this phenomenon. 
In a cross-sectional study, the group of De Medeiros investigated 354 
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women in menopause.45 The authors studied gynecological and mental 
symptomatology and concurrent conditions. Symptoms like hot flashes, 
anxiety, lack of memory, and low energy were found in nearly 60.0% 
of the sample. Tearfulness, depression, melancholia, and sleeplessness 
were recurrent. Menopause, psychosexual, and vasomotor symptoms 
were the most predominant disorders. Hot flashes were associated with 
anxiety, lack of memory, tearfulness, depression, and melancholia.45
 De Lorenzi, in a cross-sectional study concerning factors related to 
the frequency of sexual activity in 206 postmenopausal women found 
that menopause symptoms associated with sexual activity were “hot 
flashes (p = 0.05), irritability (p = 0.04), melancholy/sadness (p = 
0.04), arthralgia/myalgia (p < 0.01), and weakness/ tiredness (p < 
0.01)”. The authors concluded that their findings “agreed with the 
hypothesis that sexuality of climacteric women is not only influenced 
by factors related to hypoestrogenism, but also by psychosocial and 
cultural aspects associated with aging itself ”.46
Conclusion
In light of this literature review, it can be concluded that the 
inter-examiner and test-retest reliability and internal consistency 
of the various ICD and DSM diagnostic categories are quite high. 
Clinicians and researchers around the world can thus communicate 
more successfully and appropriately, using common assessment tools 
and a similar nomenclature. However, while reliability does not 
substantially compromise the validity of nosological categories such 
as schizophrenia and obsessive-compulsive disorder, many authors 
do not feel the same way in relation to other new constructs such 
as major depression, dysthymia, anxiety disorders, and personality 
disorders. This speaks in favor of the recovery of traditional or classical 
phenomenological concepts, such as melancholy, providing operational 
diagnostic criteria able to maintain the high level of agreement reached 
between clinicians without sacrificing the validity of categories The 
lack of correlations between clinical and biological data continues to 
be, according to several authors, one of the great unsolved problems 
of psychiatry today, and could be solved by recovering the value of 
traditional psychopathological analysis based on fundamental and 
thorough clinical assessment, which should underpin etiological 
research and treatment decisions. 
In order to be diagnosed with major depressive disorder, one has 
to report depressed mood or loss of interest for pleasure for a period 
of two weeks, together with other items in a list including nine 
symptoms (three or more symptoms, if the first two are present). A 
broad concept certainly does not contribute to test hypotheses about 
the etiology of depression and response to biological treatments. It does 
not serve either to assist in the decision to medicate or not those who 
fulfill these criteria. 
The concept of melancholy is much more precise and, therefore, has 
greater predictive value in the assessment of therapeutic response to 
antidepressants, for example. The authors conclude that melancholy 
is a lifetime diagnosis, characteristically with recurrent episodes. 
In the present classification, it is often seen in severely ill patients 
with major depressive disorder and with bipolar affective disorder. 
As we understand, this refers to the definition of melancholia as a 
“specifier” in the DSM, which does not provide a clear description of 
the symptoms that define melancholia as a subtype of major depression 
symptoms.
Juruena et al. argued that “the key problem in diagnosis is the fact 
that elaborated classification systems that exist today are solely based 
on subjective descriptions of symptoms.47 Such detailed phenomenology 
includes the description of multiple clinical subtypes; however, there is 
no biological feature that distinguishes one subtype from another”.47 
The authors believe that “a research approach that describes reliable 
neurobiological findings based on psychopathological syndromes will 
be more solid contrasted to a nonetiologic system of classification. 
Integrative approaches to understanding complex health issues can 
transcend disciplinary and knowledge boundaries and provide 
opportunities to view phenomena from diverse perspectives. A future 
diagnostic criteria system in which etiology and pathophysiology are 
essential in diagnostic decision making would bring psychiatry closer 
to other specialties of medicine”.47
We conclude that the relationship of melancholia with depressive 
syndromes is a good illustration of a topic that can be clarified within a 
comprehensive perspective. Latin American articles describe the clinical 
features of melancholia that have been validated through physiological 
tests and treatment response, and offer a historical and more systematic 
and operationally reliable paradigm for the classification of psychiatric 
disorders than the current symptom checklists in the ICD-10 and 
DSM-IV.
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